Complement-fixing islet cell antibodies in type-1 diabetes can trigger the assembly of the terminal complement complex on human islet cells and are potentially cytotoxic

O. Radillo, A. Nocera, A. Leprini, S. Barocci, T. E. Mollnes, M. Pocecco, M. Pausa, U. Valente, C. Betterle, F. Tedesco

Research output: Contribution to journalArticle

Abstract

Forty-one sera of patients with IDDM (insulin-dependent diabetes mellitus) containing complement-fixing islet cell antibodies were analyzed for their ability to activate TCC (terminal complement complex). Eighteen sera were found to promote deposition of TCC on human islets of pancreatic cryostat sections with a nonhomogeneous pattern of distribution corresponding to that of insulin. Activation of TCC by IDDM serum and binding of this complex to islet cells was confirmed using purified islets. Flow cytometric analysis of islet cell treated with a TCC + IDDM serum showed IgG binding to the cell surface. The same serum had a cytotoxic effect on islet cells in the presence of human C. These results obtained with a homologous system of C activation by IDDM sera suggest that TCC may contribute, at least in part, to the pancreatic β cell damage.

Original languageEnglish
Pages (from-to)217-223
Number of pages7
JournalClinical Immunology and Immunopathology
Volume79
Issue number3
DOIs
Publication statusPublished - 1996

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Complement-fixing islet cell antibodies in type-1 diabetes can trigger the assembly of the terminal complement complex on human islet cells and are potentially cytotoxic'. Together they form a unique fingerprint.

  • Cite this